Journal · Repair
Why Regenerative Peptides Don’t Work: The Cellular Battery Problem
The short answer
Every step of tissue repair needs energy. Cells get that energy from mitochondria, and mitochondrial output drops with age, chronic inflammation and metabolic disease. When it does, repair signals arrive at cells that don’t have the power to act on them. Most protocols never check for this.
Questions this article answers
Everyone is optimising the signal and ignoring the battery
Cell migration, protein synthesis, collagen deposition, immune cell activation, new blood vessel growth: all of it runs on ATP, the molecule cells use as fuel. Regenerative Resilience opens its Category 5 chapter (p. 95) on that point. When mitochondrial capacity falls, repair is energy-limited no matter what signalling compounds are used.
Think of BPC-157 or TB-500 as instructions. Instructions don’t help a crew with no fuel in the machines.
What drains the battery
The book names four things that reduce mitochondrial capacity:
- Damage to mitochondrial DNA that builds up with age.
- Lower activity in the respiratory chain, the machinery that makes ATP.
- Accumulated oxidative damage.
- Slower mitophagy, the process that clears out worn-out mitochondria.
Chronic inflammation adds to all of these, which is why older people, people with metabolic problems, and anyone with a long-running injury are the most likely to hit this wall.
The four compounds aimed at the energy problem
The book groups these as enablers. They aren’t tissue-repair compounds and they aren’t immune modulators. Their job is to restore the capacity everything else depends on.
SS-31 (elamipretide)
SS-31 concentrates at the inner mitochondrial membrane and binds cardiolipin, a fat that holds the energy-making machinery together. Protecting cardiolipin preserves efficient energy production and reduces reactive oxygen species. The status has moved since the book went to print: in September 2025 the FDA granted accelerated approval to elamipretide, sold as Forzinity, to improve muscle strength in Barth syndrome, a rare genetic disease of cardiolipin (reference 4). It is not approved for tissue repair or general use.
MOTS-c
A peptide encoded by the mitochondria’s own DNA. It activates AMPK, the cell’s energy sensor, and improves how cells use glucose and fat. The key 2015 study in Cell Metabolism showed it prevented diet-induced obesity and insulin resistance in mice (reference 1). Human data are early. More in our MOTS-c profile.
Humanin
Another mitochondria-encoded peptide. It protects cells from mitochondria-triggered cell death, with protective effects seen in neurons and heart cells in preclinical work. Fewer cells lost means more cells left to repair. Human trial data are limited.
NAD+
Not a peptide, but part of the same problem. NAD+ is a coenzyme needed for energy production, sirtuin activity and DNA repair, and levels fall with age. It has the strongest human evidence in this group: a 2018 randomised trial found that nicotinamide riboside, an NAD+ precursor, was well tolerated and raised NAD+ in healthy middle-aged and older adults (reference 3).
When the battery is the real problem
The book’s decision rule is simple: if limited energy is a plausible barrier to repair, address it. In a younger person with an acute injury and healthy mitochondria, this layer may be optional. It becomes foundational in:
- Older adults, where mitochondrial decline is expected.
- Insulin resistance and metabolic syndrome.
- Recovery after oxygen-deprivation injury to the heart, brain or kidney.
- Chronic fatigue and exhaustion after long illness or inflammation.
- Large injuries, where the building phase demands a lot of energy.
Unlike structural compounds, which matter most in the building phase, mitochondrial support is relevant across every phase. It improves conditions for everything else running at the same time.
Be honest about the evidence
The evidence for this category is uneven, and the book grades it that way. NAD+ precursors have the best human data. SS-31 has human clinical data and now one narrow FDA approval. MOTS-c and Humanin are mostly preclinical. None of the four is proven to speed up tissue repair in people. The idea is sound biology. How much it helps a given person is an open question.
Questions people ask
Why are my peptides not working?
Common reasons include an unresolved inflammatory environment, poor blood supply, a compound used in the wrong phase and, the one most often missed, limited cellular energy. Regenerative Resilience (pp. 95–98) explains why tissue with declining mitochondrial function is energy-limited regardless of which signalling compounds are used.
What are mitochondrial peptides?
Peptides that act on the mitochondria. Some are made by the mitochondria’s own DNA (MOTS-c and Humanin). Others, like SS-31, are designed to target mitochondrial membranes.
Is SS-31 FDA approved?
Elamipretide (SS-31) received FDA accelerated approval in September 2025 as Forzinity, for muscle strength in Barth syndrome only (reference 4). It isn’t approved for any other use.
Does NAD+ really decline with age?
Yes. Research reviews describe NAD+ falling with age through higher consumption and lower production (reference 2), which is why precursors such as NMN and NR are being studied.
Where this comes from in our books
This article is the plain-language version. The book sections below go further, with full mechanism detail, evidence tiers and how each idea fits a complete protocol. Page numbers refer to the print editions.
Regenerative Resilience
Section III, Category 5: Mitochondrial Regeneration Peptides · pp. 95–98
Read next
Put the framework to work
The free Protocol Builder applies the same category-first logic as the books, built from the same compound database.
Open the Protocol BuilderSee the book seriesReferences
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. View sourceCited in Regenerative Resilience (p. 352) and Metabolic Precision (p. 354)
- Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513–528. View sourceCited in Regenerative Resilience (p. 353) and Metabolic Precision (p. 355)
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. View source
- Stealth BioTherapeutics. FDA accelerated approval of FORZINITY (elamipretide HCl) for Barth syndrome. September 2025. View source
How this article is maintained. Research and regulatory status change. We review our articles against current sources and update them as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Nothing in this article is a recommendation to use any compound or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.